DELFT, The Nethe la ds, Ju e 30, 2026 (GLOBE NEWSWIRE) — AdJa e, a cli ical-stage vacci e platfo m compa y developi g i t a asal a d i t amuscula vacci es based o ative Oute Memb a e Vesicles ( OMVs), today a ou ces the publicatio of fi st-i -huma Phase I cli ical data i the pee – eviewed jou al Vacci es, demo st ati g the ability of its p op ieta y OMV platfo m to i duce both mucosal a d systemic immu e espo ses i huma s.
The fi st-i -huma a domized, double-bli d, placebo- a d OMV-co t olled t ial i 40 healthy adults demo st ated that AdJa e’s platfo m, combi ed with a SARS-CoV-2 Spike p otei a d admi iste ed i t a asally, was safe a d well tole ated a d i duced both systemic a d mucosal immu e espo ses. The combi atio t igge ed dose-depe de t systemic immu e espo ses ac oss multiple measu es, i cludi g vi us- eut alizi g a tibodies. Impo ta tly, the study showed i ductio of immu e activity at the asal mucosa — the p ima y e t y site fo ma y espi ato y pathoge s.
The fi di gs p ovide cli ical p oof-of-co cept fo AdJa e’s OMV platfo m a d suppo t its b oade applicatio ac oss espi ato y pathoge s, pa demic p epa ed ess sce a ios, a d othe i fectious disease ta gets cu e tly u de developme t.
“This publicatio ep ese ts a impo ta t validatio milesto e fo AdJa e a d ou mucosal OMV platfo m,” said A ita Gashi, Ma agi g Di ecto of AdJa e. “Cu e t i jectable vacci es a e highly effective at p eve ti g seve e disease but have show limited ability to i te upt i fectio a d t a smissio at the mucosal level. Ou Phase I data demo st ate that i t a asal OMV-based vacci atio ca safely i duce both systemic a d mucosal immu ity i huma s, suppo ti g the pote tial of ou platfo m as a ext-ge e atio app oach fo espi ato y i fectious diseases a d pa demic p epa ed ess.”
The COVID-19 pa demic highlighted a majo challe ge i i fectious disease co t ol: while i jectable vacci es ca p ovide st o g p otectio agai st seve e disease a d death, they ge e ally i duce limited immu e p otectio i the uppe espi ato y t act, whe e ma y ai bo e pathoge s i itiate i fectio a d t a smissio . This gap educes the ability of co ve tio al vacci es to limit pe so -to-pe so sp ead.
Mucosal vacci atio app oaches aim to add ess this limitatio by ge e ati g immu e espo ses di ectly at the site of pathoge e t y, while also i duci g b oade systemic p otectio . As i te est i t a smissio -blocki g immu ity a d pa demic p epa ed ess st ategies co ti ues to g ow globally, mucosal vacci atio is i c easi gly ecog ized as a impo ta t eme gi g modality i vacci e developme t.
AdJa e’s OMV platfo m is desig ed to suppo t apid adaptatio agai st eme gi g espi ato y pathoge s while e abli g scalable a d p actical deployme t st ategies.
AdJa e’s OMV platfo m is based o mo e tha th ee decades of scie tific esea ch o igi ati g f om leadi g Dutch gove me tal esea ch i stitutio s. The platfo m utilizes ative oute memb a e vesicles de ived f om Neisse ia me i gitidis bacte ia, which atu ally stimulate the immu e system while closely mimicki g bacte ial su face st uctu es.
The platfo m i co po ates fou p op ieta y ge etic modificatio s desig ed to imp ove safety, ma ufactu i g pe fo ma ce, a d deployme t flexibility, while p ese vi g the i t i sic immu ostimulato y p ope ties of the vesicles. AdJa e’s platfo m is desig ed as a modula plug-a d-play tech ology that e ables i co po atio of multiple a tige s th ough seve al e gi ee i g app oaches, suppo ti g apid vacci e developme t agai st ewly eme gi g pathoge s a d othe i fectious disease ta gets.
The platfo m is bei g applied ac oss multiple p og ams, i cludi g pa demic p epa ed ess collabo atio s ta geti g b oad-spect um espi ato y vi al p otectio i pa t e ship with CEPI, a d a timic obial esista ce applicatio s i cludi g a CARB-X-suppo ted p og am agai st multid ug- esista t Neisse ia go o hoeae, o e of the most commo ly epo ted sexually t a smitted bacte ial i fectio s espo sible fo ove 80 millio ew i fectio s a ually.
I additio , the platfo m has demo st ated stability u de sta da d ef ige atio co ditio s fo mo e tha 2.5 yea s, suppo ti g stockpili g a d b oade global deployme t without elia ce o ult a-cold supply chai s.
AdJa e is a cli ical-stage vacci e platfo m compa y developi g ext-ge e atio i t a asal a d i t amuscula vacci es based o its ative Oute Memb a e Vesicle ( OMV) platfo m tech ology. The compa y focuses o pa demic p epa ed ess, a timic obial esista ce, a d global i fectious disease challe ges.
AdJa e’s platfo m has bee scie tifically developed ove mo e tha 30 yea s by leadi g Dutch gove me tal esea ch i stitutio s a d suppo ts multiple deployme t modalities fo both p ophylactic a d the apeutic applicatio s.
AdJa e’s platfo m is p otected by a laye ed i tellectual p ope ty po tfolio cove i g a tige p ese tatio a d display tech ologies, as well as p op ieta y ma ufactu i g p ocesses a d specific applicatio s.
Fo mo e i fo matio , co tact:
A ita Gashi, Ma agi g Di ecto a ita.gashi@adja e.comwww.adja e.com
The Phase I study was a fi st-i -huma , a domized, double-bli d, placebo- a d OMV-co t olled cli ical t ial co ducted i 40 healthy SARS-CoV-2 se opositive adults aged 18–55 yea s.
Full study esults a e published i Vacci es a d a e available at https://www.mdpi.com/3957576. The t ial is egiste ed at Cli icalT ials.gov u de ide tifie NCT05604690.
